Drug Profile

HPK1 targeting tumour infiltrating lymphocytes therapy - 1St Biotherapeutics

Latest Information Update: 26 Dec 2025

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator 1St Biotherapeutics
Class Antineoplastics; Immunotherapies; Tumour infiltrating lymphocyte therapies
Mechanism of Action Immunologic cytotoxicity; Lymphocyte replacements

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity No

20 Nov 2025 Discontinued - Preclinical for Cancer in South Korea (Parenteral) (1St Biotherapeutics pipeline, November 2025)
25 Dec 2024 Preclinical trials in Cancer in South Korea (Parenteral) (1St Biotherapeutics pipeline, December 2024)

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com